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Abstract
Introduction In critically ill patients sudden changes in glomerular filtration rate (GFR) are not instantly
followed by parallel changes in serum creatinine. The aim of the present study was to analyze the utility
of serum cystatin C as a marker of renal function in these patients.
Methods Serum creatinine, serum cystatin C and 24-hour creatinine clearance (CCr) were determined
in 50 critically ill patients (age 21–86 years; mean Acute Physiology and Chronic Health Evaluation II
score 20 ± 9). They did not have chronic renal failure but were at risk for developing renal dysfunction.
Serum cystatin C was measured using particle enhanced immunonephelometry. Twenty-four-hour body
surface adjusted CCr was used as a control because it is the 'gold standard' for determining GFR.
Results Serum creatinine, serum cystatin C and CCr (mean ± standard deviation [range]) were 1.00 ±
0.85 mg/dl (0.40–5.61 mg/dl), 1.19 ± 0.79 mg/l (0.49–4.70 mg/l), and 92.74 ± 52.74 ml/min per 1.73
m2 (8.17–233.21 ml/min per 1.73 m2), respectively. Our data showed that serum cystatin C correlated
better with GFR than did creatinine (1/cystatin C versus CCr: r = 0.832, P < 0.001; 1/creatinine versus
CCr: r = 0.426, P = 0.002). Cystatin C was diagnostically superior to creatinine (area under the curve
[AUC] for cystatin C 0.927, 95% confidence interval 86.1–99.4; AUC for creatinine 0.694, 95%
confidence interval 54.1–84.6). Half of the patients had acute renal dysfunction. Only five (20%) of
these 25 patients had elevated serum creatinine, whereas 76% had elevated serum cystatin C levels
(P = 0.032).
Conclusion Cystatin C is an accurate marker of subtle changes in GFR, and it may be superior to
creatinine when assessing this parameter in clinical practice in critically ill patients.
Introduction
Glomerular filtration rate (GFR) is considered the best marker
of renal function, and serum creatinine is the most commonly
used biochemical parameter to estimate GFR in routine prac-
tice. However, there are some shortcomings to the use of this
parameter. Factors such as muscle mass and protein intake
can influence serum creatinine, leading to an inaccurate esti-
mation of GFR. Normal serum creatinine may be observed in
individuals with significantly impaired GFR [1,2]. Moreover, in
unstable, critically ill patients, acute changes in renal function
can make real-time evaluation of GFR using serum creatinine
difficult.
Cystatin C is a nonglycosylated protein that belongs to the
cysteine protease inhibitors, cystatin superfamily [3]. These
proteins play an important role in the regulation of proteolytic
damage to the cysteine proteases. Cystatin C is produced at
a constant rate by nucleated cells [4]. It is found in relatively
high concentrations in many body fluids, especially in the sem-
inal fluid, cerebrospinal fluid and synovial fluid [5]. Its low
molecular weight (13.3 kDa) and positive charge at physiolog-
ical pH levels facilitate its glomerular filtration. Subsequently, it
is reabsorbed and almost completely catabolized in the proxi-
mal renal tubule [6,7]. Therefore, because of its constant rate
of production, its serum concentration is determined by
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glomerular filtration [8-11]. Moreover, its concentration is not
influenced by infections, liver diseases, or inflammatory dis-
eases. Use of serum cystatin C as a marker of GFR is well doc-
umented, and some authors have suggested that it may be
more accurate than serum creatinine for this purpose [12-19].
The difficulties associated with monitoring and evaluating GFR
in critically ill individuals are well known. Thus far no studies
evaluating serum cystatin C as a marker of GFR in these
patients have been reported. The aim of the present study
were to determine the accuracy of serum cystatin C concen-
tration as a marker of GFR in critically ill individuals.
Methods
Fifty patients, aged 21–86 years (mean 54 years), who were
admitted to the intensive care unit at the Hospital Universitario
La Paz in Madrid, Spain between January and September
2001, were included in the study. All patients were at risk for
developing renal failure (haemodynamically unstable patients,
septic patients, individuals receiving nephrotoxic drugs and
others). Patients receiving corticoid therapy or with thyroid dis-
eases were excluded. The patients' demographic characteris-
tics and clinical conditions are summarized in Table 1.
A serum sample was drawn from each patient in the morning
(between 07:00 and 10:00) to determine serum creatinine
and serum cystatin C. A 24-hour urine sample was obtained
just before the serum sample to calculate the creatinine clear-
ance (CCr) using the following formula: CCr (ml/min) = (urine
volume × urine creatinine)/(serum creatinine × 1440).
Serum creatinine values were obtained according to standard
laboratory methods. CCr was adjusted to body surface (ml/min
per 1.73 m2). Cystatin C values were obtained using particle
enhanced immunonephelometry [10]. Normal serum creati-
nine values range from 0.6 to 1.3 mg/dl, and normal serum
cystatin C values range from 0.6 to 1 mg/l. Renal dysfunction
was defined as CCr below 80 ml/min per 1.73 m2.
Statistical analysis
The data are expressed in mean ± standard deviation (range).
Correlations between quantitative data were determined using
Pearson's test. P < 0.05 was considered statistically signifi-
cant. The diagnostic value of serum cystatin C and serum cre-
atinine for identifying renal dysfunction was evaluated using
receiver operating characteristic curve analysis, and the data
are expressed as area under the curve (AUC; 95% confidence
interval). For statistical analysis, the SPSS R 9.0 (SPSS Inc.,
Chicago, IL, USA) program was used.
Results
The mean serum creatinine concentration was 1.00 ± 0.85
mg/dl (0.40–5.61 mg/dl) and the mean serum cystatin C con-
centration was 1.19 ± 0.79 mg/l (0.49–4.70 mg/l). The mean
CCr adjusted for the body surface was 92.74 ± 52.74 ml/min
per 1.73 m2 (8.17–233.21 ml/min per 1.73 m2).
A decline in CCr was followed by an increase in levels of serum
creatinine and serum cystatin C (Fig. 1). The inverse of the
serum cystatin C and serum creatinine levels were plotted
against CCr to determine the relationships of those parameters
to this marker of renal function (Fig. 2a,b). There were signifi-
cant correlations between CCr and 1/serum creatinine (r =
0.426, P = 0.002) and between CCr and 1/serum cystatin C (r
= 0.832, P < 0.001).
Twenty-five out of the 50 patients enrolled in the study had
renal dysfunction (CCr <80 ml/min per 1.73 m2). Five (20%) of
these 25 patients with renal dysfunction had elevated serum
creatinine concentrations, whereas 19 (76%) of them had
Table 1
Demographic characteristics and clinical conditions of 50 critically ill patients at risk for developing acute renal dysfunction
Parameter Details
Age (years; mean [range]) 54 (21–86)
Sex (male/female) 34/16
APACHE II score (mean ± SD) 20 ± 9
Disease
Multiple trauma 10/50 (20%)
Pulmonary disease 10/50 (20%)
Neurological disease 9/50 (18%)
Sepsis/septic shock 9/50 (18%)
Cardiological disease 7/50 (14%)
Postsurgical high risk 5/50 (10%)
APACHE, Acute Physiology and Chronic Health Evaluation; SD, standard deviation.Available online http://ccforum.com/content/9/2/R139
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elevated serum cystatin C levels at the time of renal dysfunc-
tion (P = 0.032). On the other hand, serum creatinine levels
were within normal ranges in all patients with normal CCr (>80
ml/min per 1.73 m2) whereas 23 (92%) of them had normal
concentrations of serum cystatin C.
Nonparametric receiver operating characteristic plots of sen-
sitivity and specificity of serum creatinine and cystatin C for
detecting renal dysfunction are shown in Fig. 3. The AUC for
serum creatinine was 0.694 (95% confidence interval 54.1–
84.6) and the AUC for serum cystatin C was 0.927 (95% con-
fidence interval 86.1–99.4).
Discussion
Monitoring renal function is extremely important in the man-
agement of critically ill patients. GFR, which can be measured
by determining the clearance of various substances, is the
'gold standard' parameter for monitoring renal function. The
ideal endogenous marker would be characterized by stable
production rate, stable circulating levels (unaffected by patho-
logical changes), lack of protein binding, free glomerular filtra-
tion, and lack of reabsorption or secretion; to date, no such
marker has yet been identified. Some substances such as cre-
atinine, urea, β2-microglobulin and retinol-binding protein have
been used as endogenous markers of GFR, by measuring
either their plasma levels or their renal clearance. Among them,
the most useful markers for assessing GFR are serum creati-
nine and renal CCr. This is secondary to their correlations with
the renal clearance of some exogenous substances (inulin,
creatinine-EDTA, iothalamate) that are considered 'gold stand-
ards' for determining GFR.
Creatinine production changes significantly according to the
muscle mass of the body and dietetic factors. It is filtered by
Figure 1
Relationships of (a) serum creatinine and (b) serum cystatin C to creatinine clearance (CCr) Relationships of (a) serum creatinine and (b) serum cystatin C to creatinine clearance (CCr).
Figure 2
The (a) inverse of serum creatinine (1/creatinine) and the (b) inverse of cystatin C (1/cystatin c) were plotted against creatinine clearance (CCr) for  each of patient (P = 0.002 versus P < 0.001) The (a) inverse of serum creatinine (1/creatinine) and the (b) inverse of cystatin C (1/cystatin c) were plotted against creatinine clearance (CCr) for 
each of patient (P = 0.002 versus P < 0.001).Critical Care    April 2005  Vol 9 No 2    Villa et al.
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the glomeruli, but it is also secreted by the renal tubules. This
tubular secretion contributes approximately 20% of the total
creatinine excretion by the kidney, and it can increase as GFR
decreases. All of these factors explain why serum creatinine
concentration may not be a good parameter for accurate
determination of GFR, especially at lower rates [1].
Cystatin C production in the body is a stable process that is
not influenced by renal conditions, increased protein catabo-
lism, or dietetic factors. Moreover, it does not change with age
or muscle mass like creatinine does. Its biochemical character-
istics allow free filtration in the renal glomerulus, and subse-
quent metabolism and reabsorption by the proximal tubule. For
these reasons, serum cystatin C has been suggested to be an
ideal endogenous marker of GFR [12-19].
Most studies conducted to evaluate whether there is a role for
serum cystatin C in determining GFR involved measurement of
the clearance of exogenous substances such as creatinine-
EDTA [14,20-22], inulin [15,23], Tc-DTPA [24,25] and I-ioth-
alamate [16,26,27]. Nevertheless, CCr is still the most reliable
marker for determining GFR on a routine basis, and multiple
studies have used CCr as a control for evaluating the role for
serum cystatin C as a measure of GFR [28-30]. It is also a sim-
ple and cheap test, and, as mentioned above, its accuracy is
sufficient for determining GFR. However, measurement of CCr
can yield erroneous findings in many situations, particularly
when poor urine collection technique is employed. That the
present study was conducted in critically ill individuals, all of
whom had a bladder catheter in place, makes such errors less
likely.
Previous studies [14-16,20-22,25,27] have found a wide
range of correlations between 1/serum creatinine and clear-
ance of exogenous substances (r = 0.50–0.89). In this study
we found a correlation coefficient of 0.426 (P  = 0.002)
between CCr and 1/serum creatinine. This difference in corre-
lation rates among studies may be explained better by the
characteristics of the patients than by the methods used. Most
of the studies in the literature were performed in individuals
who were in a stable clinical condition (healthy individuals,
patients with various renal diseases, and oncological patients
undergoing chemotherapy). GFR in critically ill individuals can
change rapidly because of, for example, renal hypoperfusion
secondary to shock or the use of nephrotoxic agents. Despite
this, it is not uncommon to see changes in the serum creatinine
for up to several days until the stabilization phase is reached.
This may also explain the poor diagnostic usefulness of serum
creatinine as seen in our study (AUC 0.694) compared with
that in other studies [25]. Only five out of 25 (20%) of the indi-
viduals enrolled in our study who developed renal dysfunction
exhibited high serum creatinine levels at the time when CCr
was tested. The delay that usually exists between the decline
in GFR and that in serum creatinine makes the latter test
poorly reliable for making therapeutic decisions in critically ill
patients, such as a decision to change nephrotoxic agents or
to increase renal perfusion.
We found a strong correlation between serum cystatin C con-
centrations and CCr in this study (r = 0.832, P < 0.001). This
is similar to findings reported by other investigators (r = 0.73–
0.91) [14-16,20-22,25,27]. The diagnostic utility of cystatin C
seen in our study (AUC = 0.927) is similar to that previously
reported by other investigators [25]. The fact that most of our
patients (76%) with acute renal dysfunction had high serum
cystatin C levels at the time of CCr evaluation demonstrates
that cystatin C is a good marker for application in real time, and
suggests that serum cystatin C is a better marker of GFR than
is serum creatinine in unstable, critically ill patients (20% of
patients with acute renal dysfunction had high serum cystatin
C level).
Conclusion
In the present study we evaluated and compared serum creat-
inine and serum cystatin C as markers of GFR in unstable, crit-
ically ill patients. Our data indicate that serum cystatin C is a
good real-time marker of GFR in such patients. If this finding is
subsequently confirmed, then the simplicity of serum cystatin
C detection and its reasonable cost suggest that this test may
soon replace CCr as the biochemical marker of choice for mon-
itoring GFR in a routine practice.
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Figure 3
Nonparametric receiver operating characteristic plots of sensitivity and  specificity of serum creatinine and cystatin C Nonparametric receiver operating characteristic plots of sensitivity and 
specificity of serum creatinine and cystatin C. Area under the curve 
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Key messages
•  In this study, serum cystatin C was found to be a good 
marker of GFR.
•  Serum cystatin C was better at detecting changes in 
GFR than was serum creatinine in critically ill patients.
•  Determination of serum cystatin C levels is useful in the 
management of critically ill patients.